How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?

The SUNMO trial results have provided another option for patients with relapsed and/or refractory disease who aren't fit enough for more intensive therapy, whether it be salvage + ASCT for relapsed or CAR-T/bispecific + CIT for those with refractory disease. As well, the regimen is likely to have le...

Mosunetuzumab/polatuzumab is an effective salvage regimen for patients with R/R DLBCL (ORR 70%, CR 51%, and PFS 11.5 months) with a manageable toxicity profile. This, and other bispecific combinations, address the short PFS associated with single-agent bispecific antibody use. It is endorsed by the ...